Short Interest in Genmab A/S (OTCMKTS:GNMSF) Increases By 58.2%

Key Points

• Short interest in Genmab A/S increased by 58.2% in September, reaching 89,700 shares from 56,700 shares in August.
• The stock currently has a days-to-cover ratio of 99.7 days based on an average trading volume of 900 shares per day.
• Genmab reported an earnings per share (EPS) of $5.42, exceeding analysts' expectations of $3.99, despite revenues falling short at $925 million.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 89,700 shares, an increase of 58.2% from the August 31st total of 56,700 shares. Based on an average daily trading volume, of 900 shares, the days-to-cover ratio is currently 99.7 days. Based on an average daily trading volume, of 900 shares, the days-to-cover ratio is currently 99.7 days.

Genmab A/S Stock Performance

GNMSF stock opened at $330.00 on Monday. The stock has a fifty day moving average of $256.77 and a 200-day moving average of $222.43. Genmab A/S has a fifty-two week low of $170.00 and a fifty-two week high of $336.45. The company has a market capitalization of $21.80 billion, a price-to-earnings ratio of 16.57 and a beta of 0.95.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.99 by $1.43. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.